Cargando…

Editorial: A Time of Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies

Detalles Bibliográficos
Autores principales:	Tousi, Babak, Sabbagh, Marwan Noel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511610/ https://www.ncbi.nlm.nih.gov/pubmed/34643892 http://dx.doi.org/10.1007/s40120-021-00286-9

Ejemplares similares

5HT6 Antagonists in the Treatment of Alzheimer’s Dementia: Current Progress
por: Andrews, Megan, et al.
Publicado: (2018)

Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimer’s Disease and Related Disorders
por: Sabbagh, Marwan N.
Publicado: (2017)

RTTs-time to prepare for the advent of proton therapy
por: Wong, Sharon, et al.
Publicado: (2019)

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
por: van Dyck, Christopher H.
Publicado: (2017)

Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
por: Cummings, Jeffrey
Publicado: (2023)

Editorial Introduction
por: Sabbagh, Marwan N.
Publicado: (2016)

Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies
por: Rygiel, Katarzyna
Publicado: (2016)

Can Anti–β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?
por: Imbimbo, Bruno P., et al.
Publicado: (2020)

Advent of tirzepatide: boon for diabetic and obese?
por: Bhusal, Amrit
Publicado: (2023)

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
por: Bateman, Randall J., et al.
Publicado: (2022)

Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer’s Disease
por: Leisher, Solana, et al.
Publicado: (2023)

Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
por: Sabbagh, Marwan N., et al.
Publicado: (2019)

News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023
por: Gandy, Sam
Publicado: (2023)

Alzheimer’s disease beyond amyloid: strategies for future therapeutic interventions
por: Shi, Jiong, et al.
Publicado: (2020)

The advent of Onco-nephrology – a novel subspecialty
por: Althaf, Mohammed-Mahdi
Publicado: (2014)

Milestones of Dentistry: Advent of Anesthetics in Oral Surgery
por: Cervino, Gabriele
Publicado: (2019)

Novel Therapeutics in Alzheimer's Disease
por: Sabbagh, Marwan, et al.
Publicado: (2012)

Editorial: The chemistry of food in the advent of sustainable diets
por: Carocho, Márcio, et al.
Publicado: (2022)

The emerging role of bexarotene in the treatment of Alzheimer’s disease: current evidence
por: Tousi, Babak
Publicado: (2015)

Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer’s disease: A systematic review
por: Chowdhury, Selia, et al.
Publicado: (2023)

Immunotherapy in cervical cancer: the advent of precision medicine
por: De Felice, Francesca, et al.
Publicado: (2020)

Generation and Characterization of Anti-AA Amyloid-Specific Monoclonal Antibodies
por: Wall, Jonathan S., et al.
Publicado: (2011)

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
por: Ritchie, Craig W., et al.
Publicado: (2017)

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab
por: Shi, Mingchao, et al.
Publicado: (2022)

Advent of Elkosin
por: Banerji, Binoy
Publicado: (1950)

Editorial: Targets for Disease-Modifying Therapies in Alzheimer’s Disease, Including Amyloid β and Tau Protein
por: Parums, Dinah V.
Publicado: (2021)

Anti-amyloid: An antibody to cure Alzheimer’s or an attitude
por: Osborne, Olivia M., et al.
Publicado: (2023)

Anti-amyloid agents for treating incipient Alzheimer’s disease: a new hope?
por: Loureiro, Julia C., et al.
Publicado: (2022)

Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
por: Ritchie, Craig W., et al.
Publicado: (2018)

An international, randomized, placebo‐controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY‐DLB)
por: Lang, Frederick M., et al.
Publicado: (2021)

The Advent of Smartphone Applications in Spine Surgery: Bringing the Field to the 21st Century
por: Park, Don Young
Publicado: (2020)

The adventive flora of Tweedside
por: Hayward, Ida M.
Publicado: (1919)

The Advent of Lifestyle Medicine
por: Yeh, Byung-Il, et al.
Publicado: (2013)

The Advent of Colloidal Alkaloids
Publicado: (1917)

The Advent of Old Age
Publicado: (1873)

Second Advent of Thomsonism
Publicado: (1848)

Prescribing anti‐amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions
por: Greenberg, Barry D., et al.
Publicado: (2023)

An “epitomic” analysis of the specificity of conformation-dependent, anti-Aß amyloid monoclonal antibodies
por: Reyes-Ruiz, Jorge Mauricio, et al.
Publicado: (2020)

Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer’s Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab
por: Melo, V. S. D., et al.
Publicado: (2023)

Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease
por: Withington, Charles G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fcbbviq647hbqs0k2s0q2lafn7